儿童癌症及新型靶向治疗中尚存的挑战。
Remaining challenges in childhood cancer and newer targeted therapeutics.
作者信息
Smith Malcolm A, Reaman Gregory H
机构信息
Cancer Therapy Evaluation Program, National Cancer Institute, 9609 Medical Center Drive, RM 5-W414, MSC 9737, Bethesda, MD 20892, USA.
Office of Hematology and Oncology Products, OND, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, White Oak Building 22, Room 2202, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.
出版信息
Pediatr Clin North Am. 2015 Feb;62(1):301-12. doi: 10.1016/j.pcl.2014.09.018. Epub 2014 Oct 18.
Abstract
Despite the enormously important and gratifying advances in cancer treatment outcomes for children with cancer, cancer remains the biggest cause of death from disease in children. Because the etiology and biology of cancers that occur in children differ dramatically from those that occur in adults, the immediate extrapolation of efficacy and safety of new cancer drugs to childhood cancer indications is not possible. We discuss factors that will play key roles in guiding pediatric oncologists as they select lines of research to pursue in their quest for more effective treatments for children with cancer.
摘要
尽管儿童癌症治疗结果取得了极其重要且令人欣慰的进展，但癌症仍是儿童疾病死亡的最大原因。由于儿童癌症的病因和生物学特性与成人癌症截然不同，因此无法直接将新癌症药物的疗效和安全性外推至儿童癌症适应症。我们讨论了一些因素，这些因素将在指导儿科肿瘤学家选择研究方向以寻求更有效的儿童癌症治疗方法方面发挥关键作用。
相似文献
1
Remaining challenges in childhood cancer and newer targeted therapeutics.儿童癌症及新型靶向治疗中尚存的挑战。
Pediatr Clin North Am. 2015 Feb;62(1):301-12. doi: 10.1016/j.pcl.2014.09.018. Epub 2014 Oct 18.
2
European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.欧盟儿科立法危及全球范围内儿童癌症护理的未来及时进展。
Clin Ther. 2014 Feb 1;36(2):163-77. doi: 10.1016/j.clinthera.2014.01.009.
3
Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.儿科脑肿瘤：分子诊断、靶向和免疫治疗时代，以及对长期神经后遗症的关注。
Curr Probl Cancer. 2021 Aug;45(4):100777. doi: 10.1016/j.currproblcancer.2021.100777. Epub 2021 Jul 16.
4
Targeting pediatric solid tumors in the new era of RNA therapeutics.靶向治疗 RNA 疗法新时代的儿科实体肿瘤。
Crit Rev Oncol Hematol. 2024 Aug;200:104406. doi: 10.1016/j.critrevonc.2024.104406. Epub 2024 Jun 2.
5
Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.儿科肿瘤药物研发的监管格局：专家意见建议
Paediatr Drugs. 2021 Jul;23(4):381-394. doi: 10.1007/s40272-021-00455-1. Epub 2021 Jun 26.
6
Improving the outcome for children with cancer: Development of targeted new agents.改善癌症患儿的治疗结果：靶向新药的研发。
CA Cancer J Clin. 2015 May-Jun;65(3):212-20. doi: 10.3322/caac.21273. Epub 2015 Mar 9.
7
Integration of cancer genomics with treatment selection: from the genome to predictive biomarkers.将癌症基因组学与治疗选择相结合：从基因组到预测性生物标志物。
Cancer. 2013 Nov 15;119(22):3914-28. doi: 10.1002/cncr.28304. Epub 2013 Aug 20.
8
New approaches to therapeutic drug development for childhood cancers.儿童癌症治疗药物开发的新方法。
Curr Opin Pediatr. 2020 Feb;32(1):35-40. doi: 10.1097/MOP.0000000000000850.
9
Pediatric oncology enters an era of precision medicine.儿科肿瘤学进入了精准医学时代。
Curr Probl Cancer. 2017 May-Jun;41(3):194-200. doi: 10.1016/j.currproblcancer.2017.01.002. Epub 2017 Feb 1.
10
Landscape of early clinical trials for childhood and adolescence cancer in Spain.西班牙儿童和青少年癌症早期临床试验概况
Clin Transl Oncol. 2016 Jul;18(7):708-13. doi: 10.1007/s12094-015-1421-9. Epub 2015 Oct 21.
引用本文的文献
1
Aboriginal and Torres Strait Islander children and cancer: a narrative review of incidence, mortality, barriers to diagnosis and treatment, psychosocial needs and interventions.原住民及托雷斯海峡岛民儿童与癌症：发病率、死亡率、诊断与治疗障碍、心理社会需求及干预措施的叙述性综述
Lancet Reg Health West Pac. 2025 Mar 30;61:101530. doi: 10.1016/j.lanwpc.2025.101530. eCollection 2025 Aug.
2
Immune checkpoint inhibitors and endocrinopathies in pediatric brain tumor patients.儿童脑肿瘤患者中的免疫检查点抑制剂与内分泌病
J Pediatr Endocrinol Metab. 2024 Dec 16;38(1):58-64. doi: 10.1515/jpem-2024-0243. Print 2025 Jan 29.
3
Preclinical Systemic Pharmacokinetics, Dose Proportionality, and Central Nervous System Distribution of the ATM Inhibitor WSD0628, a Novel Radiosensitizer for the Treatment of Brain Tumors.ATM抑制剂WSD0628的临床前系统药代动力学、剂量比例关系及中枢神经系统分布，WSD0628是一种用于治疗脑肿瘤的新型放射增敏剂。
J Pharmacol Exp Ther. 2024 Jul 18;390(2):260-275. doi: 10.1124/jpet.123.001971.
4
Fractal dimension: analyzing its potential as a neuroimaging biomarker for brain tumor diagnosis using machine learning.分形维数：利用机器学习分析其作为脑肿瘤诊断神经影像生物标志物的潜力。
Front Physiol. 2023 Jul 17;14:1201617. doi: 10.3389/fphys.2023.1201617. eCollection 2023.
5
Case Report: Malignant Brain Tumors in Siblings With Mutations.病例报告：患有突变的兄弟姐妹中的恶性脑肿瘤
Front Oncol. 2022 Jul 12;12:920305. doi: 10.3389/fonc.2022.920305. eCollection 2022.
6
Postmortem brain donations vs premortem surgical resections for glioblastoma research: viewing the matter as a whole.用于胶质母细胞瘤研究的死后脑捐赠与生前手术切除：全面看待这个问题。
Neurooncol Adv. 2021 Nov 18;4(1):vdab168. doi: 10.1093/noajnl/vdab168. eCollection 2022 Jan-Dec.
7
Central nervous system tumors and three-dimensional cell biology: Current and future perspectives in modeling.中枢神经系统肿瘤与三维细胞生物学：建模的现状与未来展望
World J Stem Cells. 2021 Aug 26;13(8):1112-1126. doi: 10.4252/wjsc.v13.i8.1112.
8
The Challenges of Crizotinib Treatment in a Child With Anaplastic Large Cell Lymphoma.克唑替尼治疗儿童间变性大细胞淋巴瘤的挑战
J Pediatr Pharmacol Ther. 2021;26(6):647-654. doi: 10.5863/1551-6776-26.6.647. Epub 2021 Aug 16.
9
Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma.贫困与靶向免疫治疗：高危神经母细胞瘤儿童肿瘤组临床试验中的生存情况。
J Natl Cancer Inst. 2021 Mar 1;113(3):282-291. doi: 10.1093/jnci/djaa107.
10
The incidence of childhood cancer in Australia, 1983-2015, and projections to 2035.澳大利亚儿童癌症发病率（1983-2015 年）及 2035 年预测。
Med J Aust. 2020 Feb;212(3):113-120. doi: 10.5694/mja2.50456. Epub 2019 Dec 26.
本文引用的文献
1
The B-cell receptor pathway: a critical component of healthy and malignant immune biology.B 细胞受体通路：健康和恶性免疫生物学的关键组成部分。
Semin Hematol. 2014 Jul;51(3):206-18. doi: 10.1053/j.seminhematol.2014.05.007. Epub 2014 May 15.
2
Targeting BRAF in pediatric brain tumors.针对儿童脑肿瘤中的BRAF
Am Soc Clin Oncol Educ Book. 2014:e436-40. doi: 10.14694/EdBook_AM.2014.34.e436.
3
Declining childhood and adolescent cancer mortality.儿童和青少年癌症死亡率下降。
Cancer. 2014 Aug 15;120(16):2497-506. doi: 10.1002/cncr.28748. Epub 2014 May 22.
4
Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.从成人临床经验中吸取的教训，可为评估血管内皮生长因子通路抑制剂在儿童癌症中的应用提供参考。
Pediatr Blood Cancer. 2014 Aug;61(8):1497-505. doi: 10.1002/pbc.25036. Epub 2014 Apr 24.
5
Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications.博纳吐单抗，一种用于治疗急性淋巴细胞白血病的双特异性抗CD19/CD3双特异性T细胞衔接器（BiTE）抗体：前景与当前儿科应用
Front Oncol. 2014 Mar 31;4:63. doi: 10.3389/fonc.2014.00063. eCollection 2014.
6
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.SHH 型髓母细胞瘤的基因组测序预测了 smoothened 抑制与基因型相关的反应。
Cancer Cell. 2014 Mar 17;25(3):393-405. doi: 10.1016/j.ccr.2014.02.004.
7
Every amino acid matters: essential contributions of histone variants to mammalian development and disease.每一种氨基酸都很重要：组蛋白变体对哺乳动物发育和疾病的重要贡献。
Nat Rev Genet. 2014 Apr;15(4):259-71. doi: 10.1038/nrg3673. Epub 2014 Mar 11.
8
Antibody-modified T cells: CARs take the front seat for hematologic malignancies.抗体修饰的 T 细胞：CARs 在血液恶性肿瘤中占据主导地位。
Blood. 2014 Apr 24;123(17):2625-35. doi: 10.1182/blood-2013-11-492231. Epub 2014 Feb 27.
9
Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.药代动力学建模优化了对尤因肉瘤中“不可成药的”EWS-FLI1转录因子的抑制作用。
Oncotarget. 2014 Jan 30;5(2):338-50. doi: 10.18632/oncotarget.1495.
10
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.伊马替尼治疗儿童费城染色体阳性急性淋巴细胞白血病的长期随访：儿童肿瘤学组AALL0031研究
Leukemia. 2014 Jul;28(7):1467-71. doi: 10.1038/leu.2014.30. Epub 2014 Jan 20.
Zotero 插件